# Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

Study · id `cardio:ct-nct03176186` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03176186](<https://clinicaltrials.gov/study/NCT03176186>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03176186

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1436 participants.

## Technical summary

Registry record NCT03176186. Randomized; single masking; primary purpose treatment. Start 2026-03 (anticipated); primary completion 2029-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1436 participants (planned count; ClinicalTrials.gov record NCT03176186, source copy `cardio:ctgov-nct03176186-2025-04-03`, retrieved 2026-10-26)
- Planned start: 2026-03 (anticipated) (ClinicalTrials.gov record NCT03176186, source copy `cardio:ctgov-nct03176186-2025-04-03`, retrieved 2026-10-26)
- Primary completion: 2029-04 (anticipated) (ClinicalTrials.gov record NCT03176186, source copy `cardio:ctgov-nct03176186-2025-04-03`, retrieved 2026-10-26)
- Completion: 2030-05 (anticipated) (ClinicalTrials.gov record NCT03176186, source copy `cardio:ctgov-nct03176186-2025-04-03`, retrieved 2026-10-26)
- Countries: United States; Denmark (ClinicalTrials.gov record NCT03176186, source copy `cardio:ctgov-nct03176186-2025-04-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03176186-2025-04-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
- Acronym: XePOHCAS
- Condition: Post-Cardiac Arrest Syndrome
- Intervention (Combination product): Xenon
- Lead sponsor: Invero Pharma, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Sudden cardiac arrest (`cardio:sudden-cardiac-arrest`)

## Provenance

Content hash: 7b5c0ec2fc7ac3686f52fc553787b89fa9ae8275f4e5e25489da324b371b6eb4
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
